Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

E Castellano

Showing results (191-200 of 192) with videos related to

Pageof 20
Sort By:
You have reached the last page of results.This site can display upto 192 results.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|June 4, 2025
BRCA1/2 and homologous recombination repair alterations in high- and low-volume metastatic hormone-sensitive prostate cancer: prevalence and impact on outcomesD Olmos, D Lorente, A Jambrina, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 15, 2015
Validation of the International Metastatic Renal-Cell Carcinoma Database Consortium (IMDC) prognostic model for first-line pazopanib in metastatic renal carcinoma: the Spanish Oncologic Genitourinary Group (SOGUG) SPAZO studyB Pérez-Valderrama, J A Arranz Arija, A Rodríguez Sánchez, et al.
Pageof 20

Showing results (191-200 of 192) with videos related to

Sort By:
Pageof 20
You have reached the last page of results.This site can display upto 192 results.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|June 4, 2025
BRCA1/2 and homologous recombination repair alterations in high- and low-volume metastatic hormone-sensitive prostate cancer: prevalence and impact on outcomesD Olmos, D Lorente, A Jambrina, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 15, 2015
Validation of the International Metastatic Renal-Cell Carcinoma Database Consortium (IMDC) prognostic model for first-line pazopanib in metastatic renal carcinoma: the Spanish Oncologic Genitourinary Group (SOGUG) SPAZO studyB Pérez-Valderrama, J A Arranz Arija, A Rodríguez Sánchez, et al.
Pageof 20